Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

J App Pharm Sci. 2017; 7(5): 189-194


PEGYLATED CITRIC ACID DENDRITIC ARCHITECTURE FOR THE DELIVERY OF CYTARABINE IN TARGETING THE CANCER CELLS

B. Narasimha Rao, K. Ravindra Reddy, K. B. Chandra Sekhar.




Abstract

Current progress in nanotechnology provides a new hope for the substantial development in the success of cancer therapy particularly in controlling tumor growth and development. PEGylated citric acid dendrimers are biocompatible compounds being developed with an aim to target the myeloid cells, from which leukemia starts and spreads. Developed dendrimers also overcome the limitations observed with usual cancer therapies like drug leakage during circulation and short circulation time in blood. Cytarabine, an antimetabolite antineoplastic agent was tightly encapsulated within the dendrimer through simple complexation and targeted to tumor cells by way of high affinity interactions. PEGylation prevents the drug leakage during circulation, bypasses RES uptake by opsonins and improves drug’s stability, circulation time when administered. In present study, PEGylated citric acid dendrimers were synthesized using Divergent technique and loaded with Cytarabine. Synthesized dendrimers were evaluated for different parameters like SEM, DSC, NMR, % drug entrapment and in-vitro drug release studies etc.

Key words: Cytarabine, Acute myeloid leukemia, PEGylation, Antimetabolite, Generation






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.